drugset

drugset / Trial / NCT07160790

Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

NCT07160790 ↗

Phase 3 Not yet recruiting 321 enrolled Onconic Therapeutics Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD

Timeline

Start: 2025-09-02
Primary completion: 2026-06-30
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JP-1366	Unknown	—	—

Indications